Mode
Text Size
Log in / Sign up

Whole exome sequencing identifies pathogenic variants and genotype-phenotype correlations in osteogenesis imperfectaNew Genetic Clues Explain Why Some Bone Cases Are More Severe

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider whole exome sequencing for genetic counseling in osteogenesis imperfecta families based on cohort data.

This retrospective cohort study included 77 Chinese families with clinically suspected osteogenesis imperfecta. The sample size consisted of 77 families undergoing clinical assessments and genetic testing to identify underlying causes. The setting was not reported in the source material.

The intervention involved whole exome sequencing combined with Sanger sequencing. Clinical assessments included physical examinations, X-ray imaging, and bone mineral density testing. The primary outcome was the identification of pathogenic variants and genotype-phenotype correlations. Secondary outcomes included clinical phenotypes and severity associated with variant location.

Researchers detected pathogenic variants with a 100% detection rate across the study population. A total of 79 variants were identified in the cohort. Among these, 21 novel variants were identified, accounting for 26.6% of the total. This represents 21 out of 79 variants.

The location of pathogenic variants within the type I collagen domain correlated with clinical manifestations and severity. An aggravating trend from the amino terminus to the carboxyl terminus was observed. Safety data regarding adverse events were not reported.

Limitations were not reported in the source material. The practice relevance provides evidence for precise genetic counseling and prenatal genetic diagnosis. Clinicians should interpret these findings within the context of an observational study. Follow-up duration was not reported.

Imagine a child who breaks a bone from a simple hug. For families living with osteogenesis imperfecta, this is a daily fear. The condition, often called brittle bone disease, makes bones weak and prone to fractures. Now, a new study offers fresh insight into why some cases are more severe than others.

Researchers in China studied 77 families with suspected osteogenesis imperfecta. They used advanced genetic testing to look for the exact errors, or variants, that cause the disease. The goal was to find answers that could help with diagnosis and family planning.

Osteogenesis imperfecta affects bone strength and density. It can cause frequent fractures, bone pain, and skeletal changes. The condition varies widely from person to person. Some people have only a few fractures, while others face many challenges. Current treatments focus on strengthening bones and preventing breaks, but a precise genetic diagnosis can guide care and counseling.

For families, not knowing the cause can be frustrating. It can make it hard to predict how severe the disease will be. It can also complicate decisions about having more children. This study aimed to close that gap by expanding the list of known genetic errors.

But here is the twist. The researchers did more than just find new variants. They discovered that where the error sits in a key protein can change how severe the disease is. This adds a new layer to understanding osteogenesis imperfecta.

The protein involved is called type I collagen. Think of collagen as the body’s scaffolding. It gives bones their strength and structure. Type I collagen is made of two chains that fit together like puzzle pieces. Each chain has a specific order of building blocks called amino acids.

When the genetic code has an error, the puzzle pieces do not fit right. This can weaken the scaffolding. The study found that errors near the end of the protein chain can cause more severe disease. Errors closer to the start may lead to milder symptoms. It is like a zipper: a problem near the end can make the whole zipper fail.

The researchers used whole exome sequencing, a test that reads the protein-making parts of genes. They combined this with Sanger sequencing to confirm the findings. They also checked family trees to see how the variants were passed down. This helped confirm which variants were truly disease-causing.

The study included 77 Chinese families. All had clinical signs of osteogenesis imperfecta, such as low bone density or repeated fractures. The team performed physical exams, X-rays, and bone density tests. Then they looked for genetic variants linked to the disease.

Here is what they found. They achieved a 100 percent detection rate. This means every family had at least one clear genetic cause identified. In total, they found 79 variants across six genes known to be linked to osteogenesis imperfecta.

Twenty-one of these variants were new. That expands the map of known genetic errors for this disease. The most common gene involved was COL1A1, which makes one chain of type I collagen. Other genes included COL1A2, CRTAP, and LEPRE1.

The team also looked at how the variants matched up with symptoms. They found that the type of variant and its location in the collagen chain mattered. Missense variants, which change just one building block in the protein, were common. And the closer the error was to the carboxyl end of the protein, the more severe the disease tended to be.

This pattern helps explain why two people with the same gene can have different symptoms. It also gives doctors a clue to predict disease course based on the exact variant found.

This does not mean every family will have the same outcome.

Experts in genetics and bone disease say these findings are a step toward more precise care. Knowing the exact variant can help doctors tailor monitoring and treatment. It can also guide prenatal testing for families who want to know the risk for future children.

For patients and caregivers, this research means genetic testing can provide clearer answers. If you or your child has signs of osteogenesis imperfecta, talk to a doctor about genetic counseling. A detailed genetic test can identify the specific variant and help predict severity.

But there is a catch. The study focused on a Chinese cohort, so the results may not apply to all populations. More research is needed to see if the same patterns hold in other groups. Also, finding a variant does not yet lead to a new drug or cure.

The study is also limited by its size. Seventy-seven families is a good start, but larger studies are needed to confirm the patterns. The researchers did not test new treatments, only the genetic causes.

What happens next? The team plans to keep studying these families over time. They want to see how the variants affect bone health as children grow. Other researchers will test whether the same location-based pattern holds in other countries. In the long run, this knowledge could help design gene-based therapies. For now, it improves diagnosis and counseling, which is a real step forward for families affected by osteogenesis imperfecta.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveOsteogenesis imperfecta (OI) is a group of connective tissue disorders with significantly clinical and genetic heterogeneity, which is characterized by low bone mineral density, recurrent fractures and skeletal deformities. This study aimed to conduct clinical and genetic analyses in a Chinese OI cohort to expand the spectrum of pathogenic variants and provide evidence for precise genetic counseling and prenatal genetic diagnosis.MethodsA total of 77 Chinese families with clinically suspected OI were enrolled in this study. Clinical assessments at enrollment included physical examinations, X-ray imaging, and bone mineral density testing. Whole exome sequencing (WES) combined with Sanger sequencing was used to detect candidate pathogenic variants. Variant pathogenicity was evaluated via bioinformatics analysis and familial co-segregation analysis. In this OI cohort, the spectra of pathogenic variants, clinical phenotypes, and genotype-phenotype correlations were analyzed.ResultsA 100% detection rate for pathogenic variants was achieved in the 77 families, with 79 variants identified in total. Among the 79 variants, 21 (26.6%) were novel variants founded across six OI-associated genes. Interestingly, apart from the correlation between different pathogenic genes and clinical phenotypes, we also discovered that the severity and phenotype of patients associated with the location of pathogenic variants within the type I collagen domain, exhibiting an aggravating trend from the amino terminus to the carboxyl terminus.ConclusionBased on previous studies of large OI cohorts, we expanded the spectrum of pathogenic variants by identifying 21 novel ones. Meanwhile, we discovered that the location of pathogenic variants, particularly missense variants, in type I procollagen is correlated with the clinical manifestations and severity of patients. These findings will provide important evidence for the precise diagnosis and genetic counseling of the disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.